Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repa
- Feb 5, 2021
- 1 min read
Updated: Feb 6, 2021
Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repair status characterized from next generation sequencing
Lan Ngo
Comments